Annals of Pediatric Endocrinology & Metabolism最新文献_第4页

Impact of COVID-19 lockdown on blood glucose levels in pediatric patients with type 1 diabetes mellitus. COVID-19封锁对儿科1型糖尿病患者血糖水平的影响

IF 3.3

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448072.036

Min Hyung Cho, Young Suk Shim, Hae Sang Lee

{"title":"Impact of COVID-19 lockdown on blood glucose levels in pediatric patients with type 1 diabetes mellitus.","authors":"Min Hyung Cho, Young Suk Shim, Hae Sang Lee","doi":"10.6065/apem.2448072.036","DOIUrl":"10.6065/apem.2448072.036","url":null,"abstract":"Purpose: The coronavirus disease 2019 (COVID-19) pandemic brought stringent social distancing measures, resulting in changes to daily routines such as increased time at home, remote learning, altered meal schedules, and reduced physical activity. Therefore, we aimed to investigate the impact of the COVID-19 lockdown on glycemic control among pediatric patients with type 1 diabetes.Methods: This study retrospectively analyzed the medical records of 47 pediatric patients with type 1 diabetes who visited Ajou University Hospital before and after the lockdown. To analyze the effects of the lockdown on glycemic control, we examined the change in glycated hemoglobin (HbA1c) levels before and after the lockdown.Results: Among 47 patients, 23 (49%) were female and the average age before the lockdown as of March 2020 was 11.65±3.03 years. The mean HbA1c levels were 8.22%±1.69% and 7.86%±1.57% before and after the lockdown, respectively, showing better glycemic control during the lockdown (P=0.001). The decrease in HbA1c was more significant in subjects with higher pre-lockdown HbA1c levels, older patients, and individuals not using continuous glucose monitoring or continuous subcutaneous insulin infusion. However, from a long-term perspective, HbA1c levels at 3 years and 1 year before and after the lockdown were not significantly different.Conclusion: This study demonstrated the beneficial effect of intensive social distancing for COVID-19 on blood glucose control in pediatric patients with type 1 diabetes mellitus. Furthermore, changes due to the lockdown had a more pronounced effect on patients with existing poor glycemic control.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"25-30"},"PeriodicalIF":3.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in metrics of continuous glucose monitoring during COVID-19 in Korean children and adolescents with type 1 diabetes mellitus. 韩国1型糖尿病儿童和青少年在COVID-19期间连续血糖监测指标的变化

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448036.018

Hwa Young Kim, So Hyun Shin, Hyunju Lee, Jaehyun Kim

{"title":"Changes in metrics of continuous glucose monitoring during COVID-19 in Korean children and adolescents with type 1 diabetes mellitus.","authors":"Hwa Young Kim, So Hyun Shin, Hyunju Lee, Jaehyun Kim","doi":"10.6065/apem.2448036.018","DOIUrl":"10.6065/apem.2448036.018","url":null,"abstract":"Purpose: There are limited data regarding changes in glucose control in pediatric patients with type 1 diabetes (T1D) affected by coronavirus disease 2019 (COVID-19). This study aimed to evaluate changes in the metrics of a continuous glucose monitoring (CGM) system during COVID-19 infection in children and adolescents with T1D.Methods: Eighteen patients with T1D (<18 years of age) were included in this retrospective study. The effects of COVID-19 on CGM metrics were assessed at 5 time points (2 weeks before COVID-19 [time 1], 1 week before COVID-19 [time 2], during COVID-19 [time 3], 1 week after COVID-19 [time 4], and 2 weeks after COVID-19 [time 5]).Results: All participants had at least 1 symptom of COVID-19 and did not need to be hospitalized. The glucose management indicator (GMI) was higher at time 3 (7.7%±1.4%) compared to time 1 (7.1%±1.1%; P=0.016) and time 5 (7.0%±1.2%; P=0.008). According to the insulin delivery method, the GMI at time 3 was significantly higher than that at time 5 in patients treated with multiple daily injections (MDI) (median and interquartile range, 8.0% [6.1%-8.5%] vs. 7.1% [5.8%-7.9%]; P=0.020) but not in those treated with continuous subcutaneous insulin infusion (CSII).Conclusion: Pediatric patients with T1D and mild COVID-19 showed worsening glycemic control during COVID-19 infection, but it returned to preinfection levels within 2 weeks of infection. CSII is more effective in maintaining stable glycemic control during COVID-19 infection than is MDI therapy.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"38-44"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research advances in children's sleep and vitamin D levels. 儿童睡眠和维生素D水平的研究取得进展。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448076.038

Liuyan Zhu, Dan Yao

引用次数: 0

Association between cannabis use and risk of gynecomastia: commentary on "Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment". 大麻使用与男性乳房发育风险之间的关系。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.6065/apem.2448152.076

Jia-Lin Wu, Jun-Yang Luo, Xin-Yi Deng, Zai-Bo Jiang

引用次数: 0

Commentary on "Pediatric and adult osteoporosis: a contrasting mirror". 评论“儿童和成人骨质疏松症：一面对比鲜明的镜子”。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448244.122

Yoon-Sok Chung

引用次数: 0

Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations. 儿童生长激素缺乏症中的生长激素：临床试验和现实世界考虑的综合综述。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448258.129

Aristides K Maniatis, Michael P Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee

{"title":"Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations.","authors":"Aristides K Maniatis, Michael P Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee","doi":"10.6065/apem.2448258.129","DOIUrl":"10.6065/apem.2448258.129","url":null,"abstract":"Growth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood. pGHD is conventionally treated with daily recombinant human GH (rhGH); however, because GH therapy lasts throughout childhood, adherence to daily rhGH treatment can be low, resulting in suboptimal effectiveness. Somatrogon is a long-acting GH analog designed to address the challenges associated with daily GH therapy for pGHD. Somatrogon administered once per week is a potential alternative to daily GH therapy. The use of somatrogon is supported by phase II and III clinical trials demonstrating that once-weekly injections are noninferior to once-daily somatropin injections in terms of efficacy, safety, and tolerability and have the advantage of reduced treatment burden. This review summarizes the clinical trials of somatrogon and discusses the therapeutic profile and effects of treating pGHD with reduced injection frequency.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"11-16"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic challenges of Allan-Herndon-Dudley syndrome: a case of hypothyroidism and developmental delay. Allan-Herndon-Dudley综合征的诊断挑战：甲状腺功能减退和发育迟缓1例。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448032.016

Eun Young Joo, Myung Ji Yoo, Ji-Eun Lee, Su Jin Kim

引用次数: 0

Reply to commentary on "Gynecomastia in adolescent males: current understanding of its etiology, pathophysiology, diagnosis, and treatment". 回复关于“青春期男性男性乳房发育症：目前对其病因、病理生理、诊断和治疗的认识”的评论。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2550032.016

Kotb Abbass Metwalley

引用次数: 0

Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations". 对“儿童生长激素缺乏症中的生长激素：临床试验和现实世界考虑的综合回顾”的评论。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2524129edi01

Yoo-Mi Kim

引用次数: 0

Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. 促性腺激素释放激素激动剂治疗女孩中枢性性早熟的长期疗效。

IF 2.8

Annals of Pediatric Endocrinology & Metabolism Pub Date : 2025-02-01 Epub Date: 2025-02-28 DOI: 10.6065/apem.2448038.019

Jung Hwangbo, Eungu Kang, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee

{"title":"Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty.","authors":"Jung Hwangbo, Eungu Kang, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee","doi":"10.6065/apem.2448038.019","DOIUrl":"10.6065/apem.2448038.019","url":null,"abstract":"Purpose: This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit.Methods: We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit.Results: The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8-9 years).Conclusion: GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.","PeriodicalId":44915,"journal":{"name":"Annals of Pediatric Endocrinology & Metabolism","volume":"30 1","pages":"31-37"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0